Fund update: DNB Health Care and DNB Biotechnology

After a weak end to 2024, the healthcare sector has shown strong returns so far in 2025. The underlying drivers in the sector, both demographic and technological, are favorable. At the same time, American politics plays a role. How do we assess the outlook for the sector and our Healthcare Funds going forward?

Subtitles: Texted in English and translated using AI into Spanish, German and French. We disclaim any potential language errors in the translation. Select your preferred language or turn subtitles on/off by starting the video and clicking the speech bubble in the bottom right corner.

In this webinar, you will meet Marius Brun Haugen from DNB Wealth Management Investment Office in conversation with portfolio managers Benedicte Bakke and Rune Sand-Holm for our two healthcare funds: DNB Health Care and DNB Biotechnology. We are reviewing 2024 and the funds’ performance. Furthermore, we discuss our outlook on the market going forward, both in light of the new Trump administration in the USA and the underlying drivers for this important sector. We also touch on some of the largest investments, including Novo Nordisk.

(function() { var tag = document.createElement('script'); tag.src = "https://plausible.io/js/script.outbound-links.pageview-props.tagged-events.js"; tag.defer = true; tag.setAttribute("data-domain", "dnbam.com"); var firstScriptTag = document.getElementsByTagName('script')[0]; firstScriptTag.parentNode.insertBefore(tag, firstScriptTag); })();